Nathan J. Alves, PhD is an Assistant Professor in the Department of Emergency Medicine at the Indiana University School of Medicine and Co-Founder, President and CEO of Indiana Lysis Technologies LLC. (ILT). Dr. Alves joined the EM Department as the first non-physician tenure-track faculty member (~100 clinical faculty) following completion of a National Academy of Science Fellowship at the Naval Research Laboratory in DC. As a Chemical and Biomolecular Engineer appointed in EM, Dr. Alves is situated to develop novel methods of treating and diagnosing disease. The research he conducts is centered on the development of translational technologies, treatments, and techniques that have a positive impact on people’s lives and has resulted in 28 peer-reviewed publications and 7 patent pending technologies. His lab is highly interdisciplinary integrating synthetic biology, synthetic chemistry, analytical chemistry, and direct implementation of diverse nanoparticle formulations in both in-vitro and in-vivo disease models. ILT is an early phase nanoparticle based therapeutics company developing and commercializing safer clot digesting technologies to treat life threatening venous thrombosis, including Pulmonary Embolism (PE); and recently received 3rd place in the 2017 BioCrossroads New Venture Competition and “Best Biotech Invention” at the 2018 Notre Dame McCloskey Business Plan Competition.